Table 4.

Association between serum adiponectin, leptin, C-peptide, and homocysteine at T1 and adenoma recurrence at T4 (n = 519)

Metabolic indicator quartilesControl, n (%)Case, n (%)Any adenoma, OR (95% CI)*Case, n (%)Multiple adenoma, OR (95% CI)*Case, n (%)High-risk adenoma, OR (95% CI)*Metabolic indicator tertilesControl, n (%)Case, n (%)Advanced adenoma, OR (95% CI)*
Adiponectin (ng/mL)
    Q1 (0.08-1.94)62 (39.5)66 (42.0)130 (19.1)115 (9.6)1Q1 (0.08-2.41)82 (39.2)11 (5.3)1
    Q2 (1.95-3.16)69 (43.9)59 (37.6)0.86 (0.52-1.43)24 (15.3)0.73 (0.38-1.41)22 (14.0)1.38 (0.64-3.00)Q2 (2.42-4.40)98 (46.7)14 (6.7)1.20 (0.50-2.89)
    Q3 (3.17-5.10)67 (42.7)68 (43.3)1.03 (0.63-1.70)26 (16.6)0.88 (0.45-1.70)21 (13.4)1.46 (0.66-3.22)Q3 (4.41-17.4)97 (46.6)8 (3.8)0.61 (0.22-1.70)
    Q4 (5.11-17.4)79 (50.6)49 (31.4)0.69 (0.41-1.17)22 (14.1)0.67 (0.34-1.33)10 (6.4)0.64 (0.25-1.61)
    Ptrend0.220.340.300.30
Leptin (ng/mL)
    Q1 (0.63-4.64)55 (35.0)66 (42.0)129 (18.5)120 (12.7)1Q1 (0.63-6.06)72 (34.4)14 (6.7)1
    Q2 (4.65-9.31)66 (42.0)68 (43.3)0.87 (0.52-1.47)24 (15.3)0.79 (0.40-1.58)16 (10.2)0.78 (0.35-1.73)Q2 (6.07-13.9)94 (44.8)14 (6.7)0.66 (0.27-1.61)
    Q3 (9.32-17.3)73 (46.5)63 (40.1)0.80 (0.46-1.38)28 (17.8)0.78 (0.38-1.59)21 (13.4)0.92 (0.41-2.07)Q3 (14.0-185)111 (53.4)5 (2.4)0.22 (0.06-0.79)
    Q4 (17.4-185)83 (53.2)45 (28.8)0.64 (0.32-1.28)21 (13.5)0.69 (0.29-1.67)11 (7.1)0.58 (0.20-1.64)
    Ptrend0.220.500.340.02
C-peptide (ng/mL)
    Q1 (0.13-0.98)74 (47.4)52 (33.3)118 (11.5)111 (7.1)1Q1 (0.13-1.13)104 (49.5)10 (4.8)1
    Q2 (0.99-1.37)77 (48.4)56 (35.2)0.95 (0.56-1.59)26 (16.4)1.20 (0.59-2.44)24 (8.8)1.07 (0.44-2.62)Q2 (1.14-1.63)81 (39.3)9 (4.4)0.98 (0.36-2.66)
    Q3 (1.38-1.80)57 (37.0)67 (43.5)1.48 (0.86-2.56)28 (18.2)1.65 (0.78-3.49)19 (12.3)1.91 (0.79-4.66)Q3 (1.64-4.50)57 (37.0)14 (6.8)1.44 (0.53-3.88)
    Q4 (1.81-4.50)66 (42.9)67 (43.5)1.14 (0.66-1.99)30 (19.5)1.33 (0.62-2.85)24 (15.6)1.79 (0.74-4.34)
    Ptrend0.480.460.140.45
Homocysteine (μmol/L)
    Q1 (4.78-10.8)81 (51.3)49 (31.0)119 (12.0)112 (7.6)1Q1 (4.78-11.5)103 (49.3)11 (5.3)1
    Q2 (10.8-13.0)78 (49.7)58 (36.9)1.02 (0.61-1.71)25 (15.9)1.06 (0.52-2.15)18 (11.5)1.16 (0.50-2.69)Q2 (11.6-14.7)106 (50.7)6 (2.9)0.40 (0.14-1.16)
    Q3 (13.1-15.6)73 (46.8)58 (37.2)1.04 (0.61-1.77)26 (16.7)1.06 (0.51-2.18)16 (10.3)1.00 (0.42-2.40)Q3 (14.8-79.8)67 (32.4)16 (7.7)1.66 (0.67-4.16)
    Q4 (15.7-79.8)44 (28.6)77 (50.0)2.21 (1.27-3.86)32 (20.8)2.11 (1.01-4.40)22 (14.3)2.11 (0.89-4.97)
    Ptrend0.0030.030.080.16
  • *All comparisons against the no-polyp group (control). Multivariate OR and 95% CI models were adjusted for the baseline characteristics of age (in quartiles: <56, 56-63, 64-69, >69 y), sex, BMI (<25, 25.0-29.9, ≥30 kg/m2), and regular NSAID use. Regular NSAID use was defined as taking medication ≥1 monthly.

  • Tertiles used for advanced adenoma due to small number.

  • Reference category.

  • *All comparisons against the no-polyp group (control). Multivariate OR and 95% CI models were adjusted for the baseline characteristics of age (in quartiles: <56, 56-63, 64-69, >69 y), sex, BMI (<25, 25.0-29.9, ≥30 kg/m2), and regular NSAID use. Regular NSAID use was defined as taking medication ≥1 monthly.

  • Tertiles used for advanced adenoma due to small number.

  • Reference category.